Terns Pharmaceuticals Files 8-K
Ticker: TERN · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1831363
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Terns Pharma filed an 8-K on 12/11 for a 12/09 event. Details pending.
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on December 11, 2025, reporting an event that occurred on December 9, 2025. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. Specific details regarding the nature of the event or any financial implications are not provided in the excerpt.
Why It Matters
This filing indicates a material event has occurred for Terns Pharmaceuticals, requiring disclosure to investors. Investors should look for further details to understand the event's impact.
Risk Assessment
Risk Level: medium — An 8-K filing signals a significant event, but the lack of specific details in this excerpt necessitates caution and further investigation.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- December 09, 2025 (date) — Earliest event reported
- December 11, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 001-39926 (identifier) — Commission File Number
- 1065 East Hillsdale Blvd., Suite 100, Foster City, California 94404 (address) — Principal Executive Offices
- (650) 525-5535 (phone_number) — Registrant's Telephone Number
FAQ
What specific event is Terns Pharmaceuticals reporting on December 9, 2025?
The provided excerpt does not specify the nature of the event that occurred on December 9, 2025, only that it is being reported via an 8-K filing.
What is the significance of filing under 'Other Events' and 'Financial Statements and Exhibits'?
Filing under 'Other Events' suggests a material event not covered by other standard 8-K items, while 'Financial Statements and Exhibits' indicates that financial information or related documents are part of this filing.
When was Terns Pharmaceuticals, Inc. incorporated and in which state?
Terns Pharmaceuticals, Inc. was incorporated in Delaware.
What is the Commission File Number for Terns Pharmaceuticals, Inc.?
The Commission File Number for Terns Pharmaceuticals, Inc. is 001-39926.
Where are Terns Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices of Terns Pharmaceuticals, Inc. are located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California 94404.
Filing Stats: 1,332 words · 5 min read · ~4 pages · Grade level 13.4 · Accepted 2025-12-11 07:45:19
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
- $40.00 — ng price of the Shares to the public is $40.00 per share. The Underwriters have agreed
- $37.60 — he Underwriting Agreement at a price of $37.60 per share. The Company estimates that
- $705.8 m — from the Offering will be approximately $705.8 million, after deducting underwriting dis
Filing Documents
- d93950d8k.htm (8-K) — 34KB
- d93950dex11.htm (EX-1.1) — 207KB
- d93950dex51.htm (EX-5.1) — 9KB
- d93950dex991.htm (EX-99.1) — 10KB
- g93950g1211043746405.jpg (GRAPHIC) — 2KB
- g93950g1211044205400.jpg (GRAPHIC) — 6KB
- g93950g1211044443654.jpg (GRAPHIC) — 4KB
- 0001193125-25-315065.txt ( ) — 457KB
- tern-20251209.xsd (EX-101.SCH) — 3KB
- tern-20251209_lab.xml (EX-101.LAB) — 18KB
- tern-20251209_pre.xml (EX-101.PRE) — 11KB
- d93950d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated December 9, 2025, by and among Terns Pharmaceuticals, Inc. and Jefferies LLC, TD Securities (USA) LLC and Leerink Partners LLC, as representatives of the several underwriters named therein. 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP. 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1). 99.1 Press Release dated December 9, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: December 11, 2025 By: /s/ Caryn McDowell Caryn McDowell Chief Legal Officer and Corporate Secretary